Phase 2 N=18 A Multi-centre Study Comparing the Effects of AZD2927 and Placebo on the Electrical Activity in the Heart in Patients
Arrhythmia
Primary: Left Atrial Effective Refractory Period — 2.5; 5; 2.5; 10.8 msec
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=71 Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
HIV · HIV Infections
Primary: The Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) Less Than 50 Copies/mL at Week 24 — 89.6; 87.0 percentage of participants
Phase 2 N=133 MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ
DCIS
Primary: Local Control Rate for Follow-up Period of 5 Years. — 99 percentage of subjects
Phase 2 N=8 Rituximab in the Treatment of Patients With Bullous Pemphigoid
Bullous Pemphigoid
Primary: Primary Safety Endpoint — 0; 0; 1 participants
Phase 2 N=15 Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C
Hepatitis C
Primary: Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration — 1 participants
Phase 2 N=191 Coronary MDCTA With Iopamidol Injection 370
Coronary Artery Disease
Primary: Diagnostic Quality of Visualization of Coronary Arteries, Off-Site Reader 1 — 949; 842; 841 Segments Visualized Accurately — p=0.0099
Phase 2 N=19 A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer
Epithelial Ovarian Cancer · Extraovarian Peritoneal Cancer · Fallopian Tube Carcinoma
Primary: Number of Participants Demonstrating Clinical Response — 19 participants
Phase 2 N=9 Lokomat Versus Strength Training in Chronic Incomplete Spinal Cord Injury
Spinal Cord Injury
Primary: 10 Meter Walking at Preferred Speed — 0.04; 0.06 meters per second
Phase 2 N=746 A Peer-Oriented HIV Prevention Outreach Program for Individuals at High Risk for HIV and Other STIs
HIV Infections · Sexually Transmitted Diseases
Primary: Sex Risk Behaviors: Number of Sex Partners (>=2 Sex Partners) — 17; 29; 50; 53 participants — p=<0.01
Phase 2 N=26 Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma
Metastatic Melanoma
Primary: Complete Response — 7; 3 Participants
Phase 2 N=46 Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
Thymoma · Thymic Carcinoma
Primary: Best Overall Response by RECIST Criteria (Version 1.0) — 3; 0; 5; 6 Participants
Phase 2 N=33 Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
Gastric Cancer
Primary: Number of Patients With Each Response in "Good Risk" Genotype (Thymidylate Synthase Promoter Enhancer Region [TSER]*2/*2 or TSER*2/*3 Genotype [Low TS Expression]) — 0…
Phase 2 N=218 Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer
Neoplasms · Cancer of the Ovary
Primary: Number of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Based on the Analysis by an Independent Review…
Phase 2 N=127 Study of the Safety, Tolerability and Analgesic Efficacy of Multiple Doses of Ketorolac Tromethamine (IN) for Postoperative Pain
Postoperative Pain
Primary: Total Morphine Sulfate (MS) Use in Milligrams by Patient-controlled Analgesia (PCA) Through 24 Hours — 54.32; 37.77; 56.45 mg
Phase 2 N=36 Islet Transplantation for Type 1 Diabetes
Diabetes Mellitus, Insulin-Dependent
Primary: Percent of Participants That Achieved Insulin Independence With Adequate Control of Blood Glucose Levels at One Year Post Final Islet Transplantation. — 44; 14; 17; 14…